Abbott Laboratories Valuation Report — Built for Valuation Professionals

This comprehensive valuation report applies a full Discounted Cash Flow (DCF) and Market Multiples approach to Abbott Laboratories (ABT), designed for professionals who need structured, data-backed valuation insights.

Developed from Abbott’s 2024 Annual Report, peer filings, and Finbox data, the model integrates WACC, terminal growth sensitivity, stress testing, and blended valuation scenarios — the same analytical rigor used by investment banking and equity research teams.

What’s Inside

• Full DCF Model Walkthrough: Forecast assumptions, WACC calculation (7.8%), terminal growth (3%), and sensitivity analysis.
• Comparable Companies Analysis: Peer benchmarking with BDX, SYK, GEHC, EW, CNMD, and LMAT.
• Buy-Side Investment Lens: Equity value interpretation ($128/share DCF base case), portfolio positioning, and catalyst watchpoints.
• Stress Testing: FX, pricing, and margin compression simulations to assess downside resilience.
• Final Recommendation: “Core Hold / Add on Weakness” — rationale supported by financials, growth catalysts, and valuation math.

Perfect for:

• Valuation professionals in investment banking, equity research, or private equity
• Corporate finance managers conducting internal DCF appraisals
• Portfolio managers and investors seeking intrinsic value analysis
• Consultants and accountants preparing independent business valuations

Why It Matters

This report doesn’t just show the number — it shows the thinking behind the number.
It’s crafted for professionals who value consistency, transparency, and defensible assumptions when assessing fair value.